Inter- and intra-patient variability has also been discussed as limitation for the molecular gene fusion BCR::ABL as a surrogate endpoint in clinical trials of CML (37). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.